Bone turnover biomarkers (e.g., osteocalcin, procollagen type I N-terminal propeptide, and collagen type I cross-linked C-telopeptide) have been measured in individuals with NAFLD, but none of these bone biomarkers have been shown to correlate with NAFLD in meta-analysis. The gene discussed is COL1A2; the disease is metabolic dysfunction-associated steatotic liver disease.